Clinical trials: open to volunteers, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.
Hyperlipidemia
A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants.
- Trial name
- NCT07799688
- Testing
- HRS-7249 Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT07843862
- Testing
- HRS-4729 Injection, Mazdutide
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Psoriasis Vulgaris
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants
This Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral dose of HRS-4139 in healthy participants.
- Trial name
- NCT07802964
- Testing
- HRS-4139 Tablet
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Weight Management, Type 2 Diabetes
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation study that examines the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants and multiple administrations in obese…
- Trial name
- NCT07841860
- Testing
- HRS-1596
- Where
- China
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8…
- Conditions
- Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
- Trial name
- NCT07807059
- Testing
- HRS-4729
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Fluid Retention Caused by Heart Failure
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention
- Trial name
- NCT07318103
- Testing
- HRS-9057 injection set, 5% Glucose Injection or 0.9% sodium chloride injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Atherosclerotic Cardiovascular Disease
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease.
- Trial name
- NCT07551492
- Testing
- HRS9531
- Where
- China
- Volunteers
- 9,262 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis
The purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.
- Trial name
- NCT07660848
- Testing
- HRS-4729 Injection, HRS9531 Injection
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Prevention of Postoperative Nausea and Vomiting
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for…
- Trial name
- NCT07709897
- Testing
- HRS5580 for injection combined with palonosetron hydrochloride;, HRS5580 for injection combined with palonosetron hydrochloride, HRS5580 for injection blank preparation combined with palonosetron hydrochloride
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chronic Management of Body Weight
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
- Trial name
- NCT07670884
- Testing
- HRS9531 Tablet
- Where
- 2 sites in China
- Volunteers
- 675 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with…
- Trial name
- NCT07606950
- Testing
- HRS-5635 Injection
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
T2DM
A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus
The aim of the trial is to investigate the efficacy and safety of HRS9531 tablets versus placebo in participants with type 2 diabetes mellitus who failed to achieve adequate glycemic control on lifestyle intervention alone or on…
- Trial name
- NCT07599410
- Testing
- HRS9531 Tablet
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Participants With Obesity and Knee Osteoarthritis
A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
- Trial name
- NCT07709910
- Testing
- Ribupatide Injection
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight or Obesity
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes.
- Trial name
- NCT07690826
- Testing
- HRS-4729 Injection, HRS-4729 Injection;
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Weight Management, Type 2 Diabetes
A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants
The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.
- Trial name
- NCT06506175
- Testing
- HRS9531 tablets
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Weight Loss
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function
This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531…
- Trial name
- NCT07540754
- Testing
- HRS9531 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
The study is being conducted to evaluate the efficacy and safety of HRS9531 compared with placebo in participants with type 2 diabetes mellitus not adequately controlled with basal insulin, with or without metformin and/or…
- Trial name
- NCT07060456
- Testing
- HRS9531
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chronic Hepatitis B
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
- Trial name
- NCT06425341
- Testing
- HRS-5635 Injection, HRS-5635 Injection (low dose) and Peg-IFN-α, HRS-5635 Injection (high dose) and Peg-IFN-α
- Where
- China
- Volunteers
- 369 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Bstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
- Trial name
- NCT06974851
- Testing
- HRS9531
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Overweight
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.
- Trial name
- NCT06934408
- Testing
- HRS-5817 Injection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.